Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Using a micro-organism to make a protein or polypeptide
Reexamination Certificate
2006-06-14
2008-11-18
Kam, Chih-Min (Department: 1656)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Using a micro-organism to make a protein or polypeptide
C435S252700, C435S253600, C424S811000, C424S236100, C424S239100
Reexamination Certificate
active
07452697
ABSTRACT:
Chromatographic processes and systems for purifying abotulinumtoxin from an APF fermentation medium.
REFERENCES:
patent: 4401683 (1983-08-01), Thompson
patent: 6558926 (2003-05-01), Demain et al.
patent: 7148041 (2006-12-01), Donovan
patent: 7160699 (2007-01-01), Wang et al.
patent: 7354740 (2008-04-01), Xiang et al.
patent: 2003/0008367 (2003-01-01), Oguma
patent: 2003/0118598 (2003-06-01), Hunt et al.
patent: 2004/0235139 (2004-11-01), Demain et al.
patent: WO 94/09115 (1993-10-01), None
patent: WO 96/05222 (1995-06-01), None
patent: WO 98/54296 (1998-05-01), None
patent: WO 01/05997 (2000-07-01), None
patent: WO 01/05997 (2000-07-01), None
patent: WO 01-36655 (2000-10-01), None
patent: WO 01/58472 (2001-02-01), None
patent: WO 2005/035749 (2004-08-01), None
Tse et al. , Eur. J. Biochem. 122, 493-500 (1982).
Gimenez et al. , Applied and Environmental Microbiology 2827-2830 (1987).
Siegel, L.S., et al.,Toxin Production by Clostridium botulinum Type A Under Various Fermentation Conditions, Applied and Envirmonmental Microbiology, Oct. 1979, pp. 606-611.
Huhtanen, C.N.,Some Observations on a Perigo-Type Inhibition of Clostridium botulinum in a Simplified Medium, J. Milk Food Technol., Dec. 1975, vol. 38, No. 12, pp. 761-763.
Schantz, E.J., et al.,Use of Crystalline Type A Botulinum Toxin in Medical Research, Biomedical Aspects of Botulism, Academic Press, Inc., edited by George E. Lewis, Jr., 1981, pp. 143-150.
Whitmer, Mary E., et al.,Development of Improved Defined Media for Clostridium botulinum Serotypes A, B, and E, Applied and Environmental Microbiology, Mar. 1988, vol. 54, No. 3, pp. 753-759.
Heenan, C. N., et al., Lehensm.-Wiss. U.-Technol, 35 (2002), pp. 171-176.
Miwa, Norinaga, et al., International Journal of Food Microbiology, 49 (1999), pp. 103-106.
Mueller, J. H., et al., J. Bacteriology, Mar. 1954, 67(3), pp. 271-277.
Whitmer, M. E., et al., Applid and Environmental Microbiology, Mar. 1988, 54(3), pp. 753-759.
Oxoid—Product CM0149—product description, pp. 1-2, date unknown.
Coligan, et al.,Current protocols in protein science, Front Matter, Aug. 2003.
Lungdahl, L.G., et al., Working with anaerobic bacteria,Manual of Industrial Microbiology and Biotechnology, Chp. 8, 1986, pp. 84-96.
Mueller, J.H., et al., Variable factors influencing the product of tetanus toxin,J. Bacteriol, 1954; 67:271-7.
Ozutsumi, K., et al., Rapid, simplified method for production and purification of tetanus toxin,Applied and Environmental Microbiology, Apr. 1985, vol. 49, No. 4, pp. 939-943.
Chp. 1, pp. 1-88, Strategies of Protein Purification and Characterization,Current Protocols in Protein Science, Front Matter, (2003) John E. Coligan, et al., Ed, Chp. 21, pp. 1-282.
Chp. 21, pp. 1-282, Peptidases,Current Protocols in Protein Science, Front Matter, (2003) John E. Coligan, et al., Ed.
Bonventre, P.F., et al., Physiology of toxin production byClostridium botulinumtypes A and B,College of Medicine, vol. 7, pp. 372-374, (1959).
Chen, F., et al., Biophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component and the 900-kilodalton botulinum toxin complex species,Infect ImmunJun. 1998;66(6):2420-2425.
Holdeman, L., et al., A study of the nutritional requirements and toxin production ofClostridium botulinumtype F,Canadian Journal of Microbiology, vol. 11, (1965), pp. 1009-1019.
Johnson, E., et al.,Clostridium botulinumand its neurotoxins: a metabolic and cellular perspective,Toxicon39 (2001) 1703-1722.
Karasawa, T., et al., A defined growth medium for clostridium difficle,Microbiology(1995), 141, 371-375.
Kohl, A., et al., Comparison of the effect of botulinum toxin A (BOTOX®) with the highly-purified neurotoxin (NT201) n the extensor digitorum brevis muscle test,Mov Disord, 2000;15(Suppl 3):165.
Lewis, K.H., et al., Practical media and control measures for highly toxic cultures ofClostridium botulinumtype A,Production of Botulinum Toxin, pp. 213-230, (1947).
Li, Y., et al., Expression and characterization of the heavy chain of tetanus toxin: reconstitution of the fully-recombinant dichain protein in active form,J Biochem(Tokyo) Jun. 1999;125(6):1200-1208.
Naumann, M., et al., Botulinum toxin type A in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions,Euro. J. Neurology1999:6(Suppl 4):S111-S115.
Porfirio, Z., et al., Specific peptides of casein pancreatic digestion enhance the production of tetanus toxin,J. of Applied Microbiology, 1997 83:678-684.
Ragona, Rosario Marchese, et al., Management of Parotid Sialocele with botulinum toxin,the Laryngoscope, 109:Aug. 1999:pp. 1344-1346.
Siegel, L.S., Fermentation kinetics of botulinum toxin production (types A, B and E),Biomedical aspects of botulism, New York: Academic Press 1981:pp. 121-128.
Schantz, E.J., et al., Preparation and characterization of botulinum toxin type A for human treatment, Jankovic J, ed.;Neurological Disease and Therapy. Therapy withBotulinum Toxin, 1994;25:pp. 41-49.
Schantz, E.J., et al., Properties and use of botulinum toxin and other microbial neurotoxins in medicine,Microbiological Reviews, Mar. 1992, p. 80-99.
Schiefer-Ullrich, H., et al., Comparative studies on physiology and taxonomy of obligatory purinolytic clostridia,Arch Microbiol, 1984, 138:345-353.
Whitmer, M.E., et al., Development of improved defined media for clostridium botulinum serotypes A, B and E,Applied and Environmental Microbiology, Mar. 1988, vol. 54, No. 3, p. 753-759.
Bedu-Addo, F., et al. “Use of Biophysical characterization in preformulation development of a heavy-chain fragment of botulinum serotype B: Evaluation of suitable purification process conditions.”Pharmaceutical Research21.8 (2004): 1353:1361.
Byrne, M., et al. “Purification, potency, and efficacy of the botulinum type A binding domain from Pichia Pastoris as a recombinant vaccine candidate.”Infection and Immunity66.10 (1998): 4817-4822.
Gessler, F., et al. “Production and purification ofClostridium botulinumtype C and D neurotoxin.”FEMS Immunology and Medical Microbiology24 (1999): 361-367.
Johnson, S., et al. “Scale-up of the fermentation and purification of the recombinant heavy chain fragment C of botulinum neurotoxin serotype F, expressed in Pichia Pastoris.”Protein Expression and Purification32 (2003): 1-9.
Kozaki, S., et al. “Immunological characterization of papain-induced fragments ofClostridium botulinumtype A neurotoxin and interaction of the fragments with brain synaptosomes.”Infection and Immunity57.9 (1989): 2634-2639.
Prabakaran, S., et al. “Botulinum neurotoxin types B and E: Purification, limited proteolysis by endoproteinase Glu-C and Pepsin, and comparison of their indentified cleaved sites relative to the three-dimensional structure of type A neurotoxin.”Toxicon39 (2001): 1515-1531.
Weatherly, G., et al. “Initial purification of recombinant botulinum neurotoxin fragments for pharmaceutical production using hydrophobic charge induction chromatography.”Journal of Chromatography A952 (2002): 99-110.
Young-Perkins, et al.Journal of Food Science52 (1987): 1084-1088.
Donovan Stephen
Luo Mingjiang
Xiang Hui
Yu Yao
Allergan Inc.
Donovan Stephen
Kam Chih-Min
Nassif Claude L.
Voet Martin
LandOfFree
Chromatographic method and system for purifying a botulinum... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chromatographic method and system for purifying a botulinum..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chromatographic method and system for purifying a botulinum... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4035831